Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tandem High-Dose Therapy With Melphalan and Total Marrow Irradiation (TMI) With Peripheral Blood Progenitor Cell Support and Lenalidomide Maintenance in Multiple Myeloma: A Phase I/II Trial

NCT00112827 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT00112827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00112827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tandem High-Dose Therapy With Melphalan and Total Marrow Irradiation (TMI) With Peripheral Blood Progenitor Cell Support and Lenalidomide Maintenance in Multiple Myeloma: A Phase I/II Trial
Lead sponsor
City of Hope Medical Center
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2004
Completion date
February 15, 2019
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma, smoldering multiple myeloma, stage i multiple myeloma, stage ii multiple myeloma, stage iii multiple myeloma